Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
Type:
Grant
Filed:
April 3, 2023
Date of Patent:
November 21, 2023
Assignee:
Flare Therapeutics Inc.
Inventors:
Jonathan E. Wilson, James E. Audia, Jacob I. Stuckey
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
Type:
Grant
Filed:
June 23, 2022
Date of Patent:
November 14, 2023
Assignees:
President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Type:
Grant
Filed:
June 13, 2022
Date of Patent:
October 24, 2023
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Christopher Lange, Viengkham Malathong, Darren J. McMurtrie, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
Abstract: Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.
Type:
Grant
Filed:
October 10, 2022
Date of Patent:
October 24, 2023
Assignee:
ANEBULO PHARMACEUTICALS, INC.
Inventors:
Joseph Fenton Lawler, Daniel Pawel Schneeberger
Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.
Type:
Grant
Filed:
July 15, 2021
Date of Patent:
October 17, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Philippe Fernandes, Paul J. Krawczuk, Mark S. Tichenor
Abstract: Vaccination is the most prevalent prophylactic means for controlling seasonal influenza infections. However, an effective vaccine usually takes at least 6 months to develop for the circulating strains. Therefore, new therapeutic options are needed for acute treatment of influenza infections to control this virus and prevent epidemic/pandemic situations from developing. Described herein are fast-acting, orally active acylated amino-substituted heterocyclyl compounds effective to control this virus. In one aspect, described herein is a method of treating an influenza infection in a subject comprising administering to the subject the compounds described herein.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
October 17, 2023
Assignees:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, CHICAGO BIOSOLUTIONS, INC.
Inventors:
Lijun Rong, Irina Gaisina, Gregory R. Thatcher, Norton Peet
Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
October 17, 2023
Assignee:
ESCIENT PHARMACEUTICALS, INC.
Inventors:
Marcos Sainz, Adam Yeager, Brandon Selfridge, Esther Martinborough, Marcus Boehm, Liming Huang
Abstract: Disclosed are methods of making delmopinol and delmopinol salts (e.g., delmopinol metal salts, such as, for example, delmopinol calcium salts, delmopinol sodium salts, delmopinol potassium salts, and/or delmopinol magnesium salts).
Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
October 3, 2023
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
Abstract: The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
Abstract: Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R1, R2, R3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
September 26, 2023
Assignee:
FUJIAN HAIXI PHARMACEUTICALS CO., LTD
Inventors:
Yan Feng, Ruyong Wang, Junqing Li, Jianjia Zheng, Xin Lian, Xuan Gong, Yueli Fu, Xinshan Kang
Abstract: Described herein is an environmentally friendly process for preparing pure sulfentrazone having tank-mix compatibility which includes treating sulfentrazone with a base and isolating the pure sulfentrazone with an acid. Compositions containing the pure sulfentrazone are also included.
Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Type:
Grant
Filed:
August 30, 2021
Date of Patent:
September 19, 2023
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Christopher Lange, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
Abstract: The present invention provides a compound having the structure: a processing of making the compound; and a process of using the compound as a reagent for the difluoromethoxylation and trifluoromethoxylation of arenes or heteroarenes.
Type:
Grant
Filed:
February 26, 2019
Date of Patent:
September 19, 2023
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YROK
Abstract: Disclosed are compounds comprising ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) chemically conjugated to one or more oxoacids, amino acids, polyethylene glycols (PEG or PEO), peptides, phosphates, and/or vitamin compounds, and salts of such compounds. Also disclosed are compositions comprising at least one ketamine compound, or a salt thereof, methods of making such compounds, and methods of using such ketamine compounds and compositions.
Type:
Grant
Filed:
April 18, 2022
Date of Patent:
September 12, 2023
Assignee:
Zevra Therapeutics, Inc.
Inventors:
Guochen Chi, Sven Guenther, Travis Mickle, Adam Smith
Abstract: The present specification discloses a novel benzyloxy pyridine derivative compound represented by Chemical Formula 1, a salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and novel uses thereof. The uses comprise the uses in the preparation of a composition for activating autophagy, a composition for activating p62 protein, a composition for inducing oligomerization of p62 protein, or a composition for ameliorating, preventing or treating a disease caused by misfolded protein.
Type:
Grant
Filed:
March 18, 2022
Date of Patent:
September 12, 2023
Assignees:
AUTOTAC INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Yong Tae Kwon, Hyun Tae Kim, Jeong Eun Na, Chang Hoon Ji, Chang An Jung
Abstract: The invention in this disclosure is related to the processes of making Bindarit or derivatives thereof. Specifically, the present invention provides, in part, new processes for making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives. By way of non-limiting example, synthesis and purification processes of 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid are provided by the invention in this disclosure.
Abstract: A method of treating retinal degeneration in a subject includes administering to the subject a therapeutically effective amount of a compound of formula (I).
Type:
Grant
Filed:
December 7, 2021
Date of Patent:
September 5, 2023
Assignees:
CASE WESTERN RESERVE UNIVERSITY, UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: The present invention provides a process for preparing a compound represented by formula (VII), which comprises reacting a compound represented by formula (VI) with a malonic acid derivative in the presence of a base and an asymmetric catalyst in a two layer solvent system of hydrophobic solvent and water, (wherein R2 and R3 each independently represents a protecting group for carboxyl group).